Log In
Print
BCIQ
Print
Print this Print this
 

EPZ-5676

Also known as: DOT1L

  Manage Alerts
Collapse Summary General Information
Company Epizyme Inc.
DescriptionHistone methyltransferase DOT1L (DOT1L) inhibitor
Molecular Target Histone methyltransferase DOT1L (DOT1L)
Mechanism of ActionHistone methyltransferase DOT1L inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationLeukemia
Indication DetailsTreat acute leukemia with rearrangements of the myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene; Treat advanced hematologic malignancies, including acute leukemia with rearrangements of the myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene; Treat mixed lineage leukemia (MLL)
Regulatory Designation

U.S. - Orphan Drug (Treat advanced hematologic malignancies, including acute leukemia with rearrangements of the myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene);
EU - Orphan Drug (Treat advanced hematologic malignancies, including acute leukemia with rearrangements of the myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene)

Partner

Celgene Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today